OTCMKTS:ARGSQ Argos Therapeutics (ARGSQ) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free ARGSQ Stock Alerts $0.05 0.00 (0.00%) (As of 10/10/2019) Add Compare Share Share Today's Range$0.05▼$0.0550-Day Range$0.05▼$0.0552-Week Range$0.02▼$0.25VolumeN/AAverage Volume13,394 shsMarket Capitalization$571,698.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Argos Therapeutics alerts: Email Address Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! About Argos Therapeutics Stock (OTCMKTS:ARGSQ)Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.Read More ARGSQ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARGSQ Stock News HeadlinesSeptember 28, 2023 | investing.comARGSQ Historical DataJuly 29, 2023 | mirror.co.ukSeven Argos stores to shut NEXT month amid plans to close 100 for good by 2024April 23, 2024 | The TradingPub (Ad)At first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”June 22, 2023 | mirror.co.ukArgos launches massive half price garden furniture sale as the heatwave continuesApril 9, 2023 | marketwatch.com2023-2029 mRNA Vaccines & Therapeutics Market Opportunities and ForecastApril 6, 2023 | marketwatch.commRNA Vaccines & Therapeutics Market Share and Forecast till 2031March 21, 2023 | mirror.co.ukArgos, B&M, Iceland, Homesense and more all closing shops this month - see full listFebruary 25, 2023 | mirror.co.ukArgos to close more shops for good in Sainsbury's plan – see which branches are affectedApril 23, 2024 | The TradingPub (Ad)At first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”September 9, 2022 | dailymail.co.ukOutrage as Argos sells G-strings for childrenSeptember 8, 2022 | dailymail.co.ukArgosSee More Headlines Receive ARGSQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Argos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2017Today4/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:ARGSQ CUSIPN/A CIK1105533 Webwww.argostherapeutics.com Phone919-287-6300FaxN/AEmployees21Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.90 million Price / Sales0.30 Cash FlowN/A Price / Cash FlowN/A Book Value($1.63) per share Price / Book-0.03Miscellaneous Outstanding Shares10,587,000Free FloatN/AMarket Cap$571,698.00 OptionableNot Optionable Beta2.47 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Charles A. Nicolette (Age 57)Consultant Mr. Jeffrey D. Abbey (Age 57)Consultant & Director Dr. Richard D. Katz (Age 55)Consultant Ms. Lori R. Harrelson CPA (Age 50)CPA, VP of Fin. Mr. William N. WoffordSec.Key CompetitorsAditxtNASDAQ:ADTXImmunoCellular TherapeuticsOTCMKTS:IMUCDBellerophon TherapeuticsNASDAQ:BLPHAllarity TherapeuticsNASDAQ:ALLRSkinvisibleOTCMKTS:SKVIView All Competitors ARGSQ Stock Analysis - Frequently Asked Questions How have ARGSQ shares performed in 2024? Argos Therapeutics' stock was trading at $0.0540 at the start of the year. Since then, ARGSQ stock has increased by 0.0% and is now trading at $0.0540. View the best growth stocks for 2024 here. How were Argos Therapeutics' earnings last quarter? Argos Therapeutics Inc (OTCMKTS:ARGSQ) announced its quarterly earnings data on Wednesday, August, 9th. The biopharmaceutical company reported ($4.20) EPS for the quarter, beating analysts' consensus estimates of ($4.50) by $0.30. The biopharmaceutical company earned $0.07 million during the quarter, compared to analysts' expectations of $0.10 million. When did Argos Therapeutics' stock split? Argos Therapeutics's stock reverse split before market open on Friday, January 19th 2018. The 1-20 reverse split was announced on Thursday, January 18th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Argos Therapeutics? Shares of ARGSQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ARGSQ) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithSHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeHow to camouflage a factory of 53,000 workersStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Argos Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
